EuropaBio appoints Ronald Jager as Director for Healthcare Biotechnology

EuropaBio recently announced that Ronald Jager has been appointed Director for Healthcare Biotechnology.

Mr. Jager joins EuropaBio after over 15 years in the healthcare industry of which 10 years with Pfizer. Ronald holds a Masters in both Corporate Law and Corporate Communications which he employed while working for Pfizer as Corporate Communications Manager in the Netherlands and then as an Associate Director for Pfizer Worldwide as part of public affairs-, policy- and stakeholder engagement teams at an international level. Ronald also led an international industry association in Geneva for a year and more recently, was managing his own business in stakeholder- and reputation management as well as acting as part-time lecturer at the TIO University for Applied Sciences in the Netherlands.

Commenting on the appointment EuropaBio Secretary General, Nathalie Moll said: “We are delighted to appoint Ronald to lead the work of the Healthcare Biotech team. He takes on his new role at a dynamic time for EuropaBio and for its members. Arguments in favour of the value of healthcare biotechnology have never been more compelling in terms of wellbeing, quality of life, and economic benefits for society as the technology evolves at astonishing speed.”

“Getting inspiration from the value of healthcare, having fascination for the incredible potential of biotechnology and practicing commitment to bring its enormous benefits to society. That’s what will drive me in this new exciting role” remarked Jager.

Moll concluded: “The Healthcare Biotech Team at EuropaBio led by Ronald and its member companies and associations look forward to continuing to work with stakeholders and regulators, with the aim of developing and implementing a clear strategy for supporting one of the most crucial industries for our society as a whole.”